Nemolizumab in prurigo nodularis up to 100 weeks: <scp>OLYMPIA LTE</scp> interim analysis

Authors

Institutions

Publication Details

Journal
Journal of the European Academy of Dermatology and Venereology
Published
2025-12-17
DOI
https://doi.org/10.1111/jdv.70266
Citations
2
Primary Topic
Dermatology and Skin Diseases
Type
article
Field-Weighted Citation Impact
4.01

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Nemolizumab in prurigo nodularis up to 100 weeks: OLYMPIA LTE interim analysis

Lone Skov, Andrew Pink, Christophe Piketty, Gil Yosipovitch et al.
2 citations
Journal of the European Academy of Dermatology and Venereology
Dermatology and Skin Diseases
4.01
article

Nemolizumab in prurigo nodularis up to 100 weeks: OLYMPIA LTE interim analysis

Lone Skov, Andrew Pink, Christophe Piketty, Gil Yosipovitch, Sonja Ständer, Vivian Laquer, S. Barbarot, Zarif K. Jabbar‐Lopez, Curdin Conrad, Aliene Noda, Athanasios Tsianakas, Adam Reich, Franz J. Legat, Martin Metz, Shawn G. Kwatra, Elke Weißhaar, Jacek Cezary Szepietowski, Maxwell Benjamin Sauder, Diamant Thaçi, L. Misery, Xiaoxiao Chen, Raja Sivamani, Serge Boulinguez
article en
2 citations

Abstract

No abstract available for this paper.
Journal of the European Academy of Dermatology and Venereology
University of Maryland, Baltimore (US), University of Miami (US), Université Fédérale de Toulouse Midi-Pyrénées (FR), King's College London (GB), University of Toronto (CA), Guy's and St Thomas' NHS Foundation Trust (GB), Medical University of Graz (AT), Heidelberg University (DE), University Hospital Heidelberg (DE), Gentofte Hospital (DK), Orange Coast Memorial Medical Center (US), Centre Hospitalier Universitaire de Nantes (FR), University Hospital Münster (DE), Zentralklinik Bad Berka (DE), Galderma (United States) (US), Probity Medical Research (CA), Centre Hospitalier Régional Universitaire de Brest (FR), University Dermatology (US), St. Petersburg State Medical Academy "City Polyclinic №44" (RU), West Coast Fertility Centers (US), Life Medical Control (France) (FR), Galderma (Switzerland) (CH), AGH University of Krakow (PL), Charité - Universitätsmedizin Berlin (DE), University of Lübeck (DE), Nantes Université (FR), University of Lausanne (CH), University of Rzeszów (PL)
Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, Sanofi, Biogen, Teva Pharmaceutical Industries, Celgene, Regeneron Pharmaceuticals, Celldex Therapeutics, Fresenius Medical Care North America, Kiniksa Pharmaceuticals, Incyte, Argenx, Horizon Therapeutics, Galderma, InflaRx, LEO Pharma, Samsung, UCB Pharma
Openalex Percentile: Top 6%
Dermatology and Skin Diseases
4.01
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.